Megna Health Announces Submission of Application to the FDA for Emergency Use Authorization of its Rapid COVID-19 IgG & IgM Antibody Test for Prescription Home Use

EXTON, PA, May 24, 2021 – Megna Health, a U.S. manufacturer of Rapid COVID Tests based in Exton, Pennsylvania, announced that it has filed a U.S. Food and Drug Administration (FDA) EUA (Emergency Use Authorization) extension for Prescription Home Use for its Rapid COVID-19 IgG/IgM Antibody Test and is preparing Read more…

Megna Health Receives Point of Care With Fingerstick, Emergency Use Authorization from the FDA for its Rapid COVID-19 IgM/IgG Combo Antibody Test

EXTON, PA. (PRWEB) APRIL 23, 2021 Megna Health announced today that its Rapid COVID-19 IgM/IgG Test, previously authorized for use under the U.S. Food and Drug Administration (FDA) Emergency Use Authorization, is now available for Point of Care Settings. The test can now be administered in CLIA-waived settings using fingerstick whole Read more…